CorrespondencePregnancy should not rule out 18FDG PET/CT for women with cancer
References (5)
- et al.
Gynaecological cancers in pregnancy
Lancet
(2012) - et al.
Haematological cancers in pregnancy
Lancet
(2012)
Cited by (10)
Radiation Absorbed Dose to the Embryo and Fetus from Radiopharmaceuticals
2022, Seminars in Nuclear MedicineCitation Excerpt :Opinions differ on what constitutes an acceptable cost-benefit ratio. Papers published by The Lancet explicitly discouraged the use of 18F-FDG in pregnant women with gynecological and hematological cancers,62,63 but such a radical stance is uncommon in the field, where most authors and scientific organizations recognize that clinically justified PET scans should be performed.64-66 More often, the necessity of performing the examination is not in question; rather, dose-optimization recommendations specific to pregnant women are made.
Performing nuclear medicine examinations in pregnant women
2017, Physica MedicaCitation Excerpt :In a series of papers about the management of pregnant women with gynecological and hematological cancers published by the Lancet, the use of 18F-FDG in pregnant women was explicitly discouraged [9,10]. It is our contention that medically justified examinations should not be withheld in pregnant women for fear of radiation exposure [11]. Once the decision to perform the examination in the pregnant patient is taken, preserving the diagnostic power of the examination is of paramount importance.
The clinical features, management and outcomes of lymphoma in pregnancy: A multicentre study by the Australasian Lymphoma Alliance
2023, British Journal of HaematologyContrast Agents during Pregnancy: Pros and Cons When Really Needed
2022, International Journal of Environmental Research and Public Health<sup>18</sup>F-FDG Fetal Dosimetry Calculated with PET/MRI
2022, Journal of Nuclear Medicine